Raw Material Tenofovir Raw Powder CAS 147127-20-6

Tenofovir More Info

Tenofovir is a nucleotide analogue reverse transcriptase inhibitor (NtRTI) that was first synthesized in the 1990s. Its chemical structure is based on an acyclic nucleoside phosphonate, which mimics the natural nucleotide adenosine monophosphate. This design allows it to be actively incorporated by reverse transcriptase into the growing DNA chain of viruses like HIV and HBV, where it acts as a chain terminator, halting viral replication. Due to its poor oral bioavailability in its original form, it was developed as prodrugs—first Tenofovir Disoproxil Fumarate (TDF) and later Tenofovir Alafenamide (TAF)—which are more efficiently absorbed and converted into the active compound, tenofovir diphosphate, inside cells. This prodrug approach was crucial to its clinical success.

Uses and Applications

The primary application of tenofovir is in the treatment and prevention of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. For HIV, it is a cornerstone of combination antiretroviral therapy (cART), forming the backbone of many first-line treatment regimens. In its TDF formulation, it is also a key component of pre-exposure prophylaxis (PrEP), a highly effective strategy to prevent HIV acquisition in at-risk individuals. For HBV, it is a first-line antiviral agent that potently suppresses viral replication. The drug is formulated almost exclusively as oral tablets, often in fixed-dose combinations with other antiretroviral agents, which simplifies treatment and improves adherence for patients.

Application Market

The market for tenofovir is massive and global, forming a critical part of the multi-billion dollar antiviral pharmaceutical market. It is on the World Health Organization's List of Essential Medicines. Following patent expirations, the market is now dominated by generic manufacturers, making the drug extremely cost-effective and accessible, particularly in low- and middle-income countries where the burden of HIV and HBV is highest. Its distribution is supported by major global health initiatives and procurement agencies. The market has evolved with the introduction of TAF, which is positioned as a premium, improved version with a better renal and bone safety profile, creating a two-tier market structure.

Important Considerations

The use of tenofovir, particularly the TDF formulation, requires monitoring for potential adverse effects. The most significant concerns are nephrotoxicity (kidney damage), including a decline in estimated glomerular filtration rate (eGFR) and Fanconi syndrome, and a reduction in bone mineral density. Regular monitoring of renal function and bone density is recommended during long-term therapy. The TAF formulation presents a lower risk for these side effects but has different lipid metabolism implications. It is contraindicated in patients with severe renal impairment. As a prescription-only medication, it must be used under medical supervision. Adherence to the prescribed regimen is critical to maintain viral suppression and prevent the development of drug resistance.